Literature DB >> 17050076

Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease.

Sa A Wang1, Naomi Galili, Jan Cerny, Eric Sechman, Su Sin Chen, Jerome Loew, Qin Liu, Oluwole Fadare, Robert Hasserjian, Dan Jones, Huma Qawi, Bruce Woda, Azra Raza.   

Abstract

The majority of chronic myelomonocytic leukemia (CMML) cases arise de novo; cases evolving from preexisting myelodysplasia (MDS) or myeloproliferative diseases have not been well-studied. We conducted the present study to determine the clinicopathologic features and to study possible underlying molecular and cytogenetic mechanisms involved in this evolution. Between April 1995 and November 2005, we identified 120 CMML cases, of which 20 (16.7%) had a previous diagnosis of MDS. Of the 20 patients with MDS, 6 had relative monocytosis at diagnosis. At the time of MDS to CMML evolution, mutations in JAK2 (V617F), FLT3 (ITD), K-ras-2, or N-ras were not acquired, and only 1 (6%) of 17 evaluable cases showed cytogenetic progression. The median time to evolution from MDS to CMML was 29 months, and the median survival following CMML development was 13 months. Three cases (17%) transformed to acute myeloid leukemia. These findings indicate that in some cases of otherwise typical MDS, the progenitor cells may have some capacity for monocytic proliferation at diagnosis and manifest rapid disease progression once a monocytic proliferation supervenes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050076     DOI: 10.1309/FU04-P779-U310-R3EE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia.

Authors:  Ana Valencia-Martinez; Alessandro Sanna; Erico Masala; Elisa Contini; Alice Brogi; Antonella Gozzini; Valeria Santini
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

2.  ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia.

Authors:  Eric Padron; Sean Yoder; Sateesh Kunigal; Tania Mesa; Jamie K Teer; Najla Al Ali; Mikkael A Sekeres; Jeffrey S Painter; Ling Zhang; Jeffrey Lancet; Jaroslaw P Maciejewski; Pearlie K Epling-Burnette; Eduardo Sotomayor; Rami S Komrokji; Alan F List
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

3.  Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.

Authors:  Jia Gu; Zhiqiong Wang; Min Xiao; Xia Mao; Li Zhu; Ying Wang; Wei Huang
Journal:  Cancer Biol Ther       Date:  2017-01-19       Impact factor: 4.742

4.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Authors:  Tetsuichi Yoshizato; Yasuhito Nannya; Yoshiko Atsuta; Yusuke Shiozawa; Yuka Iijima-Yamashita; Kenichi Yoshida; Yuichi Shiraishi; Hiromichi Suzuki; Yasunobu Nagata; Yusuke Sato; Nobuyuki Kakiuchi; Keitaro Matsuo; Makoto Onizuka; Keisuke Kataoka; Kenichi Chiba; Hiroko Tanaka; Hiroo Ueno; Masahiro M Nakagawa; Bartlomiej Przychodzen; Claudia Haferlach; Wolfgang Kern; Kosuke Aoki; Hidehiro Itonaga; Yoshinobu Kanda; Mikkael A Sekeres; Jaroslaw P Maciejewski; Torsten Haferlach; Yasushi Miyazaki; Keizo Horibe; Masashi Sanada; Satoru Miyano; Hideki Makishima; Seishi Ogawa
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

5.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

6.  Chronic inflammatory demyelinating polyneuropathy accompanied by chronic myelomonocytic leukemia: possible pathogenesis of autoimmunity in myelodysplastic syndrome.

Authors:  Atsushi Isoda; Atsushi Sakurai; Yoshiyuki Ogawa; Yuri Miyazawa; Akio Saito; Morio Matsumoto; Morio Sawamura
Journal:  Int J Hematol       Date:  2009-07-09       Impact factor: 2.490

7.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

8.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

9.  Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.

Authors:  An Wu; Panpan Gao; Ningning Wu; Cong Shi; Zhenya Huang; Chunmeng Rong; Ye Sun; Lixia Sheng; Guifang Ouyang; Qitian Mu
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.638

10.  Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations.

Authors:  Hakim Nm; Tam W; Philipovskiy A; Tonk V; Orazi A
Journal:  Leuk Res Rep       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.